Peak Alloy Pact With US Army Leaves CSG Stock Cold Despite Strategic Win

Shares in Dutch ammunition maker CSG fall over 6% after landmark US Army steel-casing deal lacks contract value, timeline, and revenue forecasts, overshadowing record €17bn order backlog.

The market has delivered a withering verdict on what appeared to be a major coup for CSG. Shares in the Dutch ammunition maker slid more than 6% on Monday to €16.85, even after its Federal Ammunition subsidiary secured a landmark deal granting the US Army access to its patented Peak Alloy steel-casing technology. The stock now trades roughly 50% below the January high of €33.81, with investors focusing on what the deal conspicuously lacks: hard numbers.

Under the terms of the agreement, struck on 1 June, the US military can use the high-strength steel alloy across a range of calibres up to .50, but the full "Government Purpose Rights" only transfer after CSG delivers 40 million Peak Alloy cartridge cases. The company has not disclosed a contract value, pricing structure, delivery timeline, or revenue forecast — a level of opacity that has drained the enthusiasm from an otherwise strategic milestone. The technology, launched in 2025 with the 7mm Backcountry calibre, withstands chamber pressures exceeding 80,000 PSI, enabling lighter, shorter barrels and higher velocities that have also drawn interest from several European NATO allies.

CSG’s first-quarter results, published in mid-May, already set a high bar. Revenue climbed 13.8% year-on-year to €1.544bn, with the defence segment surging 26.5%. Operating EBIT reached €372m, producing a 24.1% margin, while the order backlog hit a record €17bn. Yet the market’s reaction to the army deal suggests that a technology access agreement without immediate revenue contribution is not enough to shift sentiment, especially after a critical report by short-seller Hunterbrook Media in May raised doubts about production capacity — claims CSG formally rejected.

The 40-million-unit delivery threshold now serves as the most concrete element of the arrangement. Whether and when CSG reaches that volume will be the next test of credibility. For now, the company is sticking to its full-year guidance of €7.4bn to €7.6bn in sales and an operating margin of 24% to 25%. Investors, however, are demanding clarity on margins, timelines, and volumes before they reward the stock.

The next potential catalyst comes on 7 August, when CSG reports its half-year results. By then, the market will be watching for any sign that the US Army partnership is translating into measurable financial impact. Until that happens, the shares remain trapped between a record order book and the cold reality of an execution premium the company has yet to earn.